The short answer

The COMPETE SWITCH CV analysis was a retrospective, claims-based observational study, not a randomized clinical trial that assigned people to Ozempic or Mounjaro.

Among adults with type 2 diabetes who had been using injectable semaglutide 1 mg, the analysis reported that escalating to semaglutide 2 mg was associated with a 6% lower relative risk of a composite major adverse cardiovascular event than switching to tirzepatide. The reported adjusted hazard ratio for switching to tirzepatide versus escalating semaglutide was 1.06 (95% confidence interval 1.04 to 1.08; P=0.005).

That is an association in routine-care data. It is not evidence that Ozempic 2 mg causes better cardiovascular outcomes than Mounjaro, and it is not a 6% absolute reduction in deaths, heart attacks, or strokes.

What COMPETE SWITCH CV studied

The analysis included 636,525 U.S. adults with type 2 diabetes receiving once-weekly injectable semaglutide 1 mg before their treatment was intensified or changed. Researchers used Komodo Health claims data linked with laboratory results, covering treatment patterns from January 2018 through September 2025.

For the cardiovascular comparison, the intention-to-treat analysis included:

• 185,705 people who escalated from semaglutide 1 mg to semaglutide 2 mg
• 23,104 people who switched from semaglutide 1 mg to tirzepatide

This design asks a clinically relevant real-world question: among people already taking semaglutide 1 mg, what outcomes were observed after clinicians and patients either increased the semaglutide dose or chose to switch therapies?

It does not answer a different question: what would happen if otherwise comparable people were randomly assigned to semaglutide 2 mg or tirzepatide under a controlled trial protocol?

What the reported 6% difference means

The cardiovascular outcome was a composite of all-cause death, myocardial infarction, and stroke. The wording matters. The death component was all-cause death, not cardiovascular death.

The analysis reported a hazard ratio of 1.06 for switching to tirzepatide compared with escalating to semaglutide 2 mg. Put plainly, after statistical adjustment, the switch group had a 6% higher relative hazard of the composite outcome, or, equivalently, semaglutide 2 mg escalation was associated with a 6% lower relative risk.

What it does not tell us

The company announcement does not provide the absolute event rates needed to judge the clinical size of the difference. A relative difference can sound substantial or small depending on how often events occurred in each group. Until detailed conference materials or a full paper provide absolute risks, endpoint definitions, component-specific results, and baseline tables, readers should not translate 6% into a specific number of prevented events.

The result also should not be described as a finding that Ozempic reduced heart attacks, strokes, or deaths by 6%. It was a result for a three-part composite, and it came from an observational comparison.

Why the study cannot prove Ozempic is better for cardiovascular protection

Claims-based research can be valuable because it reflects routine care at scale. But treatment decisions are not random. Even careful statistical adjustment cannot guarantee that the two groups were comparable in every way that affects cardiovascular outcomes.

A core issue is confounding by indication. The reasons a clinician and patient choose dose escalation versus a switch may also be connected to later health outcomes.

For example, the groups may have differed in factors such as:

• Prior response to semaglutide 1 mg and prior tolerability
• Diabetes severity and cardiovascular history
• The reason for intensifying treatment
• Access, insurance coverage, and prescribing patterns
• Persistence with treatment and adherence
• Concomitant medicines
• Risk factors that claims data may not fully capture or measure consistently

The analysis adjusted for measured differences, but adjustment cannot remove effects from factors that were unmeasured, incompletely measured, or not modeled. This is why the reported association is important to investigate, but cannot establish causation.

Dose exposure complicates the comparison

The comparison is sometimes framed as Ozempic 2 mg versus Mounjaro. In practice, exposure to tirzepatide was not uniform across the switch group.

People switching to tirzepatide initially received 2.5 mg or 5 mg, and only about 31% reached at least 10 mg during follow-up. The available report does not provide dose-duration distributions, persistence, or adherence measures for each group.

That matters because this was not necessarily a comparison between semaglutide 2 mg and a sustained, higher-dose tirzepatide strategy for every switcher. It compared the treatment pathways that occurred in real-world care.

How this fits with randomized cardiovascular evidence

COMPETE SWITCH CV should not be treated as equivalent to a randomized cardiovascular-outcomes trial.

For semaglutide, the randomized SUSTAIN-6 trial found a lower risk of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke with semaglutide versus placebo in adults with type 2 diabetes at high cardiovascular risk. That trial did not compare semaglutide 2 mg with tirzepatide.

For tirzepatide, the randomized SURPASS-CVOT trial compared tirzepatide with dulaglutide in people with type 2 diabetes and established atherosclerotic cardiovascular disease. Tirzepatide was noninferior, but not statistically superior, to dulaglutide for cardiovascular death, myocardial infarction, or stroke. It was not a semaglutide-versus-tirzepatide trial.

These trials cannot be ranked against each other by comparing percentages across publications. They used different populations, comparators, doses, endpoints, and follow-up settings.

Notably, a separate clinical-practice analysis comparing semaglutide and tirzepatide reported broadly similar cardiovascular benefit in broader real-world populations with elevated cardiovascular risk, obesity, and diabetes. That study was also observational, with different eligibility criteria and analytic methods. Together, the differing real-world findings reinforce why a single observational result should not settle the Ozempic versus Mounjaro question.

What this means if you take Ozempic or Mounjaro

This analysis does not establish that people using Mounjaro should switch to Ozempic, or that people escalating Ozempic should expect a proven cardiovascular advantage over Mounjaro.

Treatment selection is individualized. Current diabetes guidance emphasizes person-centered selection of glucose-lowering treatment and use of therapies with demonstrated cardiovascular benefits in appropriate adults with type 2 diabetes, as described in the American Diabetes Association Standards of Care.

A treatment decision can involve medical history, response and tolerability, treatment goals, access, and other factors that cannot be resolved by this analysis alone. The COMPETE SWITCH CV announcement also did not assess safety outcomes.

Bottom line

The new COMPETE SWITCH CV analysis is a large, timely real-world study. In adults with type 2 diabetes who were already using semaglutide 1 mg, escalation to semaglutide 2 mg was associated with a statistically significant 6% lower relative risk of all-cause death, myocardial infarction, or stroke than switching to tirzepatide.

But association is not proof of causation. The study was retrospective and nonrandomized, the groups followed different treatment paths, only a minority of tirzepatide switchers reached at least 10 mg, and key details such as absolute event rates are not yet available in the company announcement.

Publication-status note: These results were presented at the European Association for the Study of Diabetes Annual Meeting on September 29, 2026, and are currently reported through a company announcement and data on file. A peer-reviewed COMPETE SWITCH CV publication, full conference abstract, detailed baseline data, and independent replication may change how confidently the finding can be interpreted.